Okyo Pharma Ltd. (OKYO)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN 
OKYO Pharma reports favorable outcomes from Phase 2 neuropathic corneal pain study
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing treatments for neuropathic corneal pain (NCP), said patients treated with its investigational therapy urcosimod in its recently completed Phase 2 trial showed improvements in corneal nerve structure, a potential indicator of nerve restoration. The 18-patient, randomized, double-masked, placebo-controlled trial evaluated corneal nerve health using in vivo confocal microscopy.
OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the recently announced topline data from the company's Phase 2 trial evaluating urcosimod in patients with neuropathic corneal pain. Jacob explained that neuropathic corneal pain is a severe nerve pain condition without any FDA-approved treatments, describing it as “like having a spinal cord injury in your eye.
OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy
OKYO Pharma Ltd (NASDAQ:OKYO) announced it has secured $1.9 million in non-dilutive funding to support the development of urcosimod, its lead drug candidate for neuropathic corneal pain (NCP). NCP is a chronic, nerve-related ocular condition that currently has no US Food and Drug (FDA)-approved treatments.
OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) on Wednesday reported promising top-line results from a Phase 2 trial of its investigational drug urcosimod for neuropathic corneal pain (NCP), with 75% of patients showing greater than 80% pain reduction after 12 weeks of treatment. Patients treated with the 0.05% formulation of urcosimod saw a statistically significant reduction in pain scores compared to baseline, as measured by the Visual Analogue Scale (VAS), with an average improvement of 5.5 points versus 2.75 in the placebo group.
OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts
Shares of OKYO Pharma Ltd (NASDAQ:OKYO) have nearly doubled since the start of the year, fueled by a string of clinical and regulatory milestones that may pave the way for a transformative treatment in the underserved field of ocular pain. In a new note research report, Goldman Small Cap Research raised its price target on the stock to $8, up from $5, citing strong momentum, accelerated clinical progress, and growing interest from patients and clinicians alike in the company's lead drug candidate, urcosimod.
OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit
OKYO Pharma Ltd (NASDAQ:OKYO) shares could see renewed attention this week as the company's chief executive, Gary Jacob, is set to present findings on its lead drug candidate at a biotech conference in Boston. Jacob will speak at the GPCRs-Targeted Drug Discovery Summit on May 22, where he'll share the latest data on urcosimod, a treatment in development for neuropathic corneal pain—a chronic eye condition that causes severe discomfort and currently has no approved therapies.
OKYO moves toward FDA talks after eye drug trial – ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the early termination of its Phase 2 trial evaluating urcosimod (formerly OK-101) for neuropathic corneal pain. The company said the 48-patient study, which began in October 2024, was initially planned to continue through the end of the year.
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) announced that the US Food and Drug Administration has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP), a chronic ocular condition with no FDA-approved therapies. The designation is intended to expedite the development and review of drugs targeting serious conditions with unmet medical needs.
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to accelerate the clinical development of urcosimod, formerly called OK-101, to treat neuropathic corneal pain. The company has chosen to end its Phase 2 trial being conducted at the Tufts Medical Center in Boston, Massachusetts, early, with 17 patients having completed the study.
OKYO Pharma reports long-term shelf stability of corneal pain treatment
OKYO Pharma Ltd (NASDAQ:OKYO) said on Monday that its experimental drug urcosimod has demonstrated stability for over two and a half years in single-use ampoules. The biopharmaceutical company's confirmation that urcosimod remains stable for over two and a half years in single-use ampoules – small, sealed containers designed to hold a single dose of liquid medication – is an important step in bringing the company closer to submitting a successful New Drug Application (NDA) for FDA approval.
OKYO Pharma secures USAN designation ‘urcosimod' for lead asset
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its lead asset, OK-101, has been granted the United States Adopted Name (USAN) "urcosimod." The company said the designation reinforces its progress in developing treatments for unmet medical needs in ophthalmology, such as neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED).
OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believe
OKYO Pharma Ltd (NASDAQ:OKYO) is uniquely positioned to emerge as a key player in the ocular treatment arena as it advances its lead therapeutic candidate OK-101, analysts at Goldman Small Cap Research believe. The company is focused on developing OK-101 to treat neuropathic corneal pain (NCP), which has no Food and Drug Administration (FDA)-approved treatment.
